Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

63.51 -0.09 (-0.15%)
Streaming Delayed Price Updated: 12:05 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,690,451
Open 64.08
Bid (Size) 63.50 (600)
Ask (Size) 63.51 (300)
Prev. Close 63.60
Today's Range 63.17 - 64.35
52wk Range 42.52 - 68.64
Shares Outstanding 2,222,113,553
Dividend Yield 3.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire

Performance

YTD
+18.8%
+18.8%
1 Month
-1.7%
-1.7%
3 Month
+14.9%
+14.9%
6 Month
+7.0%
+7.0%
1 Year
+37.0%
+37.0%

More News

Read More
News headline image
3 Healthcare Stocks That Fall Short
Via StockStory
News headline image
Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗
Via The Motley Fool
Topics Intellectual Property
Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗
Via Chartmill
Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup ↗
Via Chartmill
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
Via Investor Brand Network
News headline image
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
From Bristol Myers Squibb
Via Business Wire
News headline image
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
From BioMedWire
Via GlobeNewswire
News headline image
BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗
Via The Motley Fool
News headline image
Is BioNTech Stock a No-Brainer Buy on the Dip? ↗
Via The Motley Fool
News headline image
2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Reasons to Sell BMY and 1 Stock to Buy Instead
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges
Via StockStory
Topics Stocks
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗
Via The Motley Fool
Topics ETFs
News headline image
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)
Via StockStory
Topics Artificial Intelligence Intellectual Property

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 63.51
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 09/17/26 12:05 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 141.12B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 141B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.